Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.

Alexander Kettner,Gilles DellaCorte,Fréderic de Blay,Lars Jacobsen,Marek Jutel,Margitta Worm,Vincent Charlon, Kim Simonsen,Christophe Reymond,François Spertini

Journal of Allergy and Clinical Immunology（2018）

引用 20|浏览31

暂无评分

摘要

A short course of 5 injection AIT with Bet v 1 Contiguous Overlapping Peptides was well tolerated and improved allergic rhinitis during the 2 pollen season after treatment. Long lasting efficacy was associated with a persistent allergen-specific IgG4 response.

查看译文

关键词

Bet v 1,Bet v 1 COPs,IgE,IgG4,birch pollen allergy,combined rhinoconjunctivitis symptom and medication score,desensitization,long term,specific immunotherapy,synthetic peptides

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要